Zurcher Kantonalbank Zurich Cantonalbank Purchases 2,011 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Zurcher Kantonalbank Zurich Cantonalbank grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 14.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,147 shares of the biopharmaceutical company’s stock after purchasing an additional 2,011 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ultragenyx Pharmaceutical were worth $772,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Cornercap Investment Counsel Inc. acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $246,000. WCM Investment Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 12.3% in the fourth quarter. WCM Investment Management LLC now owns 120,985 shares of the biopharmaceutical company’s stock valued at $5,840,000 after purchasing an additional 13,220 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Ultragenyx Pharmaceutical by 38.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 548 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Ultragenyx Pharmaceutical by 42.5% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 57,000 shares of the biopharmaceutical company’s stock worth $2,745,000 after purchasing an additional 17,000 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in Ultragenyx Pharmaceutical by 3,182.4% in the fourth quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 1,623 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, Director Matthew K. Fust sold 12,195 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the completion of the sale, the director now owns 14,860 shares of the company’s stock, valued at $756,076.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 4,173 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total transaction of $224,340.48. Following the transaction, the insider now owns 89,268 shares in the company, valued at approximately $4,799,047.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 12,195 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the transaction, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,116 shares of company stock valued at $1,645,983 in the last ninety days. 6.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE stock opened at $44.02 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $54.98. The company has a market capitalization of $3.62 billion, a price-to-earnings ratio of -5.28 and a beta of 0.65. The company has a 50-day simple moving average of $47.70 and a 200 day simple moving average of $43.99.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.13. The company had revenue of $127.39 million during the quarter, compared to analysts’ expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The business’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.16) earnings per share. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current year.

Analyst Ratings Changes

RARE has been the topic of several analyst reports. Robert W. Baird boosted their price target on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. TD Cowen upped their target price on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. JPMorgan Chase & Co. increased their price target on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, March 18th. Canaccord Genuity Group boosted their price target on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Finally, Wedbush reiterated a “neutral” rating and set a $48.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, April 16th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.08.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.